UNSPSC 51142023: Dixyrazine

This classification denotes a non-narcotic analgesic, antiemetic, and antipsychotic agent with the molecular formula C24H33N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7H368W3AYC, chemically known as ethanol, 2-(2-(4-(2-methyl-3-phenothiazin-10-ylpropyl)-1-piperazinyl)ethoxy)- but generally known as dixyrazine, which bears US NIH Compound Identifier 17182. European Medicines Agency schedules Dixyrazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13640MIG.

World Health Organization schedules dixyrazine in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, DIXYRAZINE remains the US FDA Preferred Term for this commodity. SMILES: S1C2C(N(CC(CN3CCN(CC3)CCOCCO)C)C3C1CCCC3)CCCC2..

UNSPSC 51142023 Dixyrazine, a Commodity code, does not align with the state and local procurement activity tagged under it. The recent solicitations tracked under this code involve naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs—none of which are dixyrazine or related to its nominal pharmaceutical scope. The mismatch suggests either a cataloging error in the source data or a misapplication of the code to pharmaceutical procurement more broadly.

The three recent opportunities span different issuing bodies and procurement stages: Seminole County, Florida posted an IFB on June 30, 2026 (due July 26, 2026) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP with a March 26, 2026 response deadline to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon; and the Texas Health and Human Services Commission posted an RFI on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program. Given the disconnect between the code's nominal substance and the actual work being bought, this code shows little actionable recent activity for vendors targeting dixyrazine procurement specifically.